Recursion Pharmaceuticals (RXRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.25
- Estimate
- -$0.23
- Surprise
- -6.8%
- Revenue (period 2026-06-30)
- $7.7M
- Score today
- 4.4/10
Revenue source: xbrl.
How the report landed
Recursion Pharmaceuticals (RXRX) reported a wider loss than forecast — diluted EPS of -$0.25 against the -$0.23 estimate (a 6.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RXRX Sell at 4.4/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -6.8% surprise compares with a +11.7% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Quality below floor (1.9 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (12 sells, 4.05% of cap)
- Momentum score 2.0/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.20
- Price target
- $6.28
- Stop
- $2.98
- Upside to target
- +96.3%
- Reward-to-risk
- 8.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
RXRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.72B
- P/E (fwd)
- -3.6
- 52-week range
- $2.77–$7.18
- Off 52-week high
- 55.4%
- RSI (14)
- 41
- Volume vs avg
- 0.51×
- Score today
- 4.4/10